FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2095776471> ?p ?o ?g. }

• W2095776471 endingPage "91" @default.
• W2095776471 startingPage "87" @default.
• W2095776471 abstract "Anagrelide is often used in the treatment of thrombocythemia in myeloproliferative disease (MPD), but information concerning effects of treatment on cytokines involved in regulation of blood platelet levels is limited. Here, we investigated serum levels of thrombopoietin (TPO) and soluble IL-6 receptor (sIL-6R) in relation to response to treatment with and plasma concentrations of anagrelide. Samples from 45 patients with thrombocythemia due to MPD (ET=31, PV=14), being treated with anagrelide for 6 months, were analyzed for TPO, sIL-6R and anagrelide levels. The mean baseline platelet count was 983x10(9)/L. A reduction of platelets to <600 in asymptomatic or <400 x 10(9)/L in symptomatic patients was defined as a complete remission (CR), a reduction with >50% of baseline as partial remission, and <50% reduction as failure. At 6 months, 35 patients were in CR, 1 had a partial remission and 9 were treatment failures. For all patients, there was an increase in TPO of 44% from baseline; this change was more pronounced for patients with partial remission and failure. sIL-6R levels did not change significantly. There was no correlation between levels of anagrelide and cytokine levels at 6 months, and changes of cytokine levels did not relate to changes of platelet counts. Thus, a pronounced increase of TPO levels after 6 months of anagrelide treatment indicated that this treatment affected a major regulatory mechanism for megakaryocyte and platelet formation in MPD." @default.
• W2095776471 created "2016-06-24" @default.
• W2095776471 creator A5003034041 @default.
• W2095776471 creator A5005190962 @default.
• W2095776471 creator A5007727741 @default.
• W2095776471 creator A5012374853 @default.
• W2095776471 creator A5033275967 @default.
• W2095776471 creator A5033506735 @default.
• W2095776471 creator A5046644939 @default.
• W2095776471 creator A5050171154 @default.
• W2095776471 creator A5057341791 @default.
• W2095776471 creator A5072934022 @default.
• W2095776471 creator A5082776643 @default.
• W2095776471 date "2008-01-01" @default.
• W2095776471 modified "2023-10-14" @default.
• W2095776471 title "TPO, but not soluble-IL-6 receptor, levels increase after anagrelide treatment of thrombocythemia in chronic myeloproliferative disorders" @default.
• W2095776471 cites W118940326 @default.
• W2095776471 cites W1968894202 @default.
• W2095776471 cites W1974301854 @default.
• W2095776471 cites W1982351131 @default.
• W2095776471 cites W1985475668 @default.
• W2095776471 cites W1993080305 @default.
• W2095776471 cites W2009954157 @default.
• W2095776471 cites W2017955228 @default.
• W2095776471 cites W2029919986 @default.
• W2095776471 cites W2030435811 @default.
• W2095776471 cites W2030450616 @default.
• W2095776471 cites W2033705843 @default.
• W2095776471 cites W2049489739 @default.
• W2095776471 cites W2050019527 @default.
• W2095776471 cites W2053620613 @default.
• W2095776471 cites W2069651950 @default.
• W2095776471 cites W2070075266 @default.
• W2095776471 cites W2078517764 @default.
• W2095776471 cites W2079061053 @default.
• W2095776471 cites W2085322522 @default.
• W2095776471 cites W2090768460 @default.
• W2095776471 cites W2092484653 @default.
• W2095776471 cites W2094499020 @default.
• W2095776471 cites W2113021948 @default.
• W2095776471 cites W2115236146 @default.
• W2095776471 cites W2116774122 @default.
• W2095776471 cites W2142632589 @default.
• W2095776471 cites W2151447594 @default.
• W2095776471 cites W2157988767 @default.
• W2095776471 cites W2168062293 @default.
• W2095776471 cites W2168793982 @default.
• W2095776471 cites W339601887 @default.
• W2095776471 cites W90455964 @default.
• W2095776471 doi "https://doi.org/10.7150/ijms.5.87" @default.
• W2095776471 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/2293642" @default.
• W2095776471 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/18414650" @default.
• W2095776471 hasPublicationYear "2008" @default.
• W2095776471 type Work @default.
• W2095776471 sameAs 2095776471 @default.
• W2095776471 citedByCount "6" @default.
• W2095776471 countsByYear W20957764712013 @default.
• W2095776471 countsByYear W20957764712016 @default.
• W2095776471 countsByYear W20957764712021 @default.
• W2095776471 crossrefType "journal-article" @default.
• W2095776471 hasAuthorship W2095776471A5003034041 @default.
• W2095776471 hasAuthorship W2095776471A5005190962 @default.
• W2095776471 hasAuthorship W2095776471A5007727741 @default.
• W2095776471 hasAuthorship W2095776471A5012374853 @default.
• W2095776471 hasAuthorship W2095776471A5033275967 @default.
• W2095776471 hasAuthorship W2095776471A5033506735 @default.
• W2095776471 hasAuthorship W2095776471A5046644939 @default.
• W2095776471 hasAuthorship W2095776471A5050171154 @default.
• W2095776471 hasAuthorship W2095776471A5057341791 @default.
• W2095776471 hasAuthorship W2095776471A5072934022 @default.
• W2095776471 hasAuthorship W2095776471A5082776643 @default.
• W2095776471 hasBestOaLocation W20957764711 @default.
• W2095776471 hasConcept C109159458 @default.
• W2095776471 hasConcept C126322002 @default.
• W2095776471 hasConcept C134018914 @default.
• W2095776471 hasConcept C2775855021 @default.
• W2095776471 hasConcept C2777863708 @default.
• W2095776471 hasConcept C2778690821 @default.
• W2095776471 hasConcept C2778837598 @default.
• W2095776471 hasConcept C2779705218 @default.
• W2095776471 hasConcept C2779788118 @default.
• W2095776471 hasConcept C2780829020 @default.
• W2095776471 hasConcept C2781057849 @default.
• W2095776471 hasConcept C28328180 @default.
• W2095776471 hasConcept C54355233 @default.
• W2095776471 hasConcept C71924100 @default.
• W2095776471 hasConcept C86803240 @default.
• W2095776471 hasConcept C89560881 @default.
• W2095776471 hasConcept C90924648 @default.
• W2095776471 hasConceptScore W2095776471C109159458 @default.
• W2095776471 hasConceptScore W2095776471C126322002 @default.
• W2095776471 hasConceptScore W2095776471C134018914 @default.
• W2095776471 hasConceptScore W2095776471C2775855021 @default.
• W2095776471 hasConceptScore W2095776471C2777863708 @default.
• W2095776471 hasConceptScore W2095776471C2778690821 @default.
• W2095776471 hasConceptScore W2095776471C2778837598 @default.
• W2095776471 hasConceptScore W2095776471C2779705218 @default.
• W2095776471 hasConceptScore W2095776471C2779788118 @default.

• next